Trial Profile

A Randomized, Observer-blind Trial to Assess the Immunogenicity and Safety of Third Dose Vaccination With AstraZeneca COVID-19 (ChAdOx1 AZD1222) Vaccine or Pfizer/BioNTech COVID-19 (BNT162b2) Vaccine Among Thai Adults Who Have Received Two Doses of Sinovac Inactivated COVID-19 Vaccine

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Apr 2023 Results comparing the immunogenicity and safety of fractional (half) third doses of heterologous COVID-19 vaccines (AZD1222 or BNT162b2) to full doses after the two-dose CoronaVac and when boosting after three different extended intervals, published in the International Journal of Infectious Diseases
03 Jul 2022 Status changed from recruiting to completed.
08 Apr 2022 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com